Shares of Cephalon Inc CEPH and Teva Pharmaceutical Industries TEVA gained in pre-market trading after TEVA agreed to purchase Cephalon for $6.8 billion.
Teva's cash offer of $81.50 per share represents a 6% premium over Cephalon closing price on Friday.
CEPH shares gained 6.01% to $81.65 in pre-market trading, while TEVA shares rose 3.32% to $47.25 in pre-market trading.
Read more from Benzinga's Company news.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsM&APre-Market OutlookMoversBiotechnologyHealth CareMergers and AcquisitionsPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in